We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

63 hedge funds and large institutions have $21.5M invested in Galectin Therapeutics in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 16

3% less funds holding

Funds holding: 65 → 63 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

63% less capital invested

Capital invested by funds: $58.6M → $21.5M (-$37.1M)

72% less call options, than puts

Call options by funds: $326K | Put options by funds: $1.15M

Holders
63
Holders Change
-2
Holders Change %
-3.08%
% of All Funds
1.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
22
Reduced
16
Closed
12
Calls
$326K
Puts
$1.15M
Net Calls
-$828K
Net Calls Change
+$717K

Top Buyers

Rank Fund Capital Flow
1
CCA
Catalyst Capital Advisors
New York
+$5.26M
2
Northern Trust
Northern Trust
Illinois
+$1.11M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$742K
4
ARTA
A.R.T. Advisors
New York
+$633K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$430K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.14M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.72M
3
Allianz Asset Management
Allianz Asset Management
Germany
-$1.92M
4
DADC
D.A. Davidson & Co
Montana
-$581K
5
Macquarie Group
Macquarie Group
Australia
-$467K
Name Holding Trade Value Shares
Change 		Change in
Stake
RIA
51
Regal Investment Advisors
Michigan
$8K +$9.35K +1,200 +400%
AA
52
Apriem Advisors
California
$8K +$12.5K +1,600 New
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$4.51K +$6.99K +897 New
LTFS
54
Ladenburg Thalmann Financial Services
Florida
$4K +$1.62K +208 +42%
IPC
55
Independent Portfolio Consultants
Florida
$3K -$5.88K -755 -57%
OIA
56
Optimum Investment Advisors
Illinois
$3K – – –
TWA
57
TCI Wealth Advisors
Arizona
$2K – – –
GSC
58
Ground Swell Capital
South Carolina
$2K +$1.81K +233 +233%
Barclays
59
Barclays
United Kingdom
$1K -$1.62K -208 -53%
PSI
60
Pinnacle Summer Investments
Virginia
$1K – – –
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$1K – – –
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$47 -$20.6K -2,650 -22%
BBA
63
Baker Bros. Advisors
New York
– -$4.14M -300,000 Closed
Allianz Asset Management
64
Allianz Asset Management
Germany
– -$1.92M -139,285 Closed
D.E. Shaw & Co
65
D.E. Shaw & Co
New York
– -$456K -33,045 Closed
SG Americas Securities
66
SG Americas Securities
New York
– -$342K -24,744 Closed
Jane Street
67
Jane Street
New York
– -$264K -19,096 Closed
MLICM
68
Metropolitan Life Insurance Company (MetLife)
New York
– -$204K -14,775 Closed
SCM
69
Stevens Capital Management
Pennsylvania
– -$184K -13,288 Closed
GC
70
Guggenheim Capital
Illinois
– -$157K -11,406 Closed
SO
71
STRS Ohio
Ohio
– -$47.5K -6,100 Closed
VFA
72
Virtus Fund Advisers
Connecticut
– -$21K -1,537 Closed
BlackRock
73
BlackRock
New York
– -$7K -491 Closed
Ameriprise
74
Ameriprise
Minnesota
– -$1K -40 Closed
AAM
75
American Asset Management
Florida
– +$654 +84 New
1 2
3

GALT Hedge Fund Activity: Q3 2014 in Review

63 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2014, worth a combined $21.5M — down 63% from $58.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GALT and 10 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 22 added.

The largest buyer was Catalyst Capital Advisors, opening a new position worth an estimated $5.26M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.14M sold.

  • 63 institutional investors held Galectin Therapeutics (GALT) as of Q3 2014, down from 65 in Q2 2014.
  • Funds reported $21.5M of Galectin Therapeutics stock for Q3 2014, down 63% quarter-over-quarter.
  • 10 funds opened new Galectin Therapeutics positions in Q3 2014 and 12 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q3 2014 was Catalyst Capital Advisors, an estimated $5.26M added.
  • The largest Galectin Therapeutics seller in Q3 2014 was Baker Bros. Advisors, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2014.